Retatrutide

What it is

Retatrutide is an investigational triple agonist — a single molecule that activates three receptors at once: GIP, GLP-1, and glucagon. The first two pathways are shared with tirzepatide; adding glucagon-receptor activity is thought to raise energy expenditure and act on hepatic fat, potentially amplifying weight loss beyond the dual-agonist ceiling. Its long half-life of roughly six days supports once-weekly injection. It is developed by Eli Lilly and has no brand name because it is not approved.

What it’s approved or studied for

It is not approved for anything. Retatrutide is being studied primarily for obesity and type 2 diabetes, with additional phase 3 trials (the TRIUMPH program) in obstructive sleep apnea and knee osteoarthritis. Everything known about it comes from clinical trials, not real-world approved use.

What human evidence exists

The headline result is the phase 2 obesity trial published in NEJM in 2023: once-weekly retatrutide produced a mean weight reduction of up to about 24% at 48 weeks on the highest dose — the largest figure yet reported for an incretin drug at that stage. A separate phase 2 diabetes trial showed strong HbA1c reductions. This is a genuinely striking signal, but it is still preliminary: the evidence rests on phase 2 trials, the confirmatory phase 3 program is only beginning to report, and there is no cardiovascular outcomes data. We grade its outcomes C (Preliminary) rather than A because the drug has not cleared the bar an approved medication has.

The major unknowns

Almost everything about long-term use is unknown: durability of weight loss, post-cessation regain, cardiovascular effects, and whether the glucagon-receptor activity carries metabolic trade-offs (glucagon agonism can raise glucose and heart rate, which trials monitored closely). A dose-dependent increase in heart rate was observed. Because retatrutide is not approved, anything marketed under its name outside a trial is an unregulated research chemical of unknown identity, purity, and dose.

Most important safety considerations

Gastrointestinal effects dominate the reported side effects, as with the rest of the class, and a dose-dependent heart-rate increase was seen. The incretin-class thyroid C-cell signal (from rodent studies) and pancreatitis caution are expected to apply, but there is no approved safety label to rely on. Given its investigational status, retatrutide should only be taken within a supervised clinical trial. This is a research summary, not medical advice — decisions belong with a clinician.